Blood Screening Market Report

Blood Screening Market Analysis By Technology (Nucleic Acid Amplification Test, ELISA, Chemiluminescence Immunoassay And Enzyme Immunoassay, Next-Generation Sequencing, And Western Blotting) And By Product (Reagent, Instrument) And Segment Forecasts, 2013 - 2024

Published: October 2016  |  90 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-215-0

Industry Insights

The global blood screening market size was valued at USD 1.6 billion in 2015 and is projected to grow at a CAGR of 10.2% over the forecast period. This high growth is attributed to rising blood donation and government initiatives.

According to the WHO, the overall blood donation rate increased from 3.4% in 2008 to 3.6% in 2010 in 30 countries of the European region. Initiatives by the various organizations and governments increase awareness about donation and screening before transfusion.

U.S. blood screening market by product, 2013 - 2024 (USD Million)

U.S. blood screening market

Furthermore, in 2010, the rate of screening for hepatitis B, hepatitis C, and HIV viruses increased as compared to previous years with almost 100% in most of the countries. To motivate volunteers, the WHO established a goal to provide safe blood access to the entire world by 2020. Such initiatives increase voluntary donations and are likely to propel the market during the forecast period.

Australia Red Cross launched two new initiatives to enhance voluntary donation on 14th June, 2016, which is a world blood donor day. The first initiative is an SMS alert and second is a toolkit that reduces the anxiety of the first-time donor and, thereby, increases voluntary donation in the country.

Product Insights

Reagent dominated in 2015 and is expected to maintain its dominance over the forecast period. Higher accuracy and specificity in detecting presence and type of various elements in small sample would drive the market.

In addition, reagents are cost-effective for customers and gives high return on investment to the vendors. High cost and reusable nature of instruments restraint the growth of instrument segment in the blood screening market during the forecast period 2016-2024.

Technology Insights

Nucleic acid amplification test is expected to grow at the fastest rate owing to its high sensitivity and specificity for viral nucleic acid. The test detects nucleic acid earlier than other screening methods and, thus, narrows the window period of HBV, HCV, and HIV infections.

NAT was introduced in the developed countries initially in 1990s and early 2000. About 33 countries in the world implemented NAT for HIV and around 27 countries for hepatitis B virus till 2014. The methods that fall under this segment are polymerase chain reaction, ligase chain reaction, and transcription mediated amplification.

ELISA accounted the second largest share of the market. The growth of this technology is attributed to continuous development to increase its specificity, low cost as compared to NAT, and increasing prevalence of infectious diseases in the Asia Pacific region. There are various ELISA generations available in the market

Blood screening market, by technology, 2015

Blood screening market

Regional Insights

In 2015, North America accounted for the largest revenue share. The presence of key industry players,increased adoption of blood screening process, stringent FDA regulations for transfusion, and greater patient affordability are responsible for maintaining its position during the forecast period.

Vela Diagnostics received CE mark for its real-time PC- based Sentosa SA ZIKV PCR Test. The blood screening test for Zikacan identify Zika virus infection in a donor. Furthermore, Roche launched next-generation viral load assay in March 2015 for HBV in Europe. It is a COBAS HBV quantitative nucleic acid test for COBAS 6800/8800 Systems. Hence, launch and adoption of such new technologies in the region is likely to further boost the industry in Europe.

Asia Pacific is the fastest growing region due to increasing awareness among people about blood donation, rising patient affordability, and growing focus of key industry players on emerging countries in the region. Japan, China, India, Singapore, and Australia are major contributing countries in the Asia Pacific region.

Competitive Insights

Some of the key players in the industry include Becton Dickinson and Company, Thermo Fisher Scientific., Ortho-Clinical Diagnostics, Inc., Danaher Corporation (Beckman Coulter), Abbott Laboratories; Bio-Rad Laboratories, Inc., Becton Dickinson and Company; F. Hoffmann-La Roche Ltd.; Grifols and Siemens AG

Development of new products and partnership or collaborations for the development and commercialization of products are the key strategies adopted by the companies to capture the market.

For instance, Grifols received CE mark for the Procleix HEV assay, which uses NAT to detect hepatitis E virus. The test was developed in partnership with Hologic, Inc. Hence, collaboration for commercialization and development is likely to propel the industry during the forecast period.

Blood Screening Report Scope

Attribute

Details

Base year for estimation

2015

Actual estimates/Historic data

2013 - 2015

Forecast period

2016 - 2024

Market representation

Revenue in USD Million & CAGR from 2016 to 2024

Regional scope

North America, Europe, Asia Pacific, Latin America & MEA

Country scope

U.S., Canada, UK, Germany, Japan, China, India, Brazil, Mexico, South Africa

Report coverage             

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the blood screening market on the basis of technology, product, and region:

  • Technology Outlook (Revenue, USD Million; 2013 - 2024)

    • Nucleic Acid Amplification Test (NAT)

    • ELISA

    • Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

    • Next-Generation Sequencing (NGS)

    • Western Blotting

  • Product Outlook (Revenue, USD Million; 2013 - 2024)

    • Reagent

    • Instrument

  • Regional Outlook (Revenue, USD Million; 2013 - 2024)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • MEA

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA